Clinical Trial Update: Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase II trial update for Anetumab Ravtansine in pre-treated mesothelin-expressing pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Anetumab Ravtansine (anetumab ravtansine)

Snippet

Sponsor: Yale University | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-01-22